scholarly journals Management of Brain and Leptomeningeal Metastases from Breast Cancer

2020 ◽  
Vol 21 (22) ◽  
pp. 8534
Author(s):  
Alessia Pellerino ◽  
Valeria Internò ◽  
Francesca Mo ◽  
Federica Franchino ◽  
Riccardo Soffietti ◽  
...  

The management of breast cancer (BC) has rapidly evolved in the last 20 years. The improvement of systemic therapy allows a remarkable control of extracranial disease. However, brain (BM) and leptomeningeal metastases (LM) are frequent complications of advanced BC and represent a challenging issue for clinicians. Some prognostic scales designed for metastatic BC have been employed to select fit patients for adequate therapy and enrollment in clinical trials. Different systemic drugs, such as targeted therapies with either monoclonal antibodies or small tyrosine kinase molecules, or modified chemotherapeutic agents are under investigation. Major aims are to improve the penetration of active drugs through the blood–brain barrier (BBB) or brain–tumor barrier (BTB), and establish the best sequence and timing of radiotherapy and systemic therapy to avoid neurocognitive impairment. Moreover, pharmacologic prevention is a new concept driven by the efficacy of targeted agents on macrometastases from specific molecular subgroups. This review aims to provide an overview of the clinical and molecular factors involved in the selection of patients for local and/or systemic therapy, as well as the results of clinical trials on advanced BC. Moreover, insight on promising therapeutic options and potential directions of future therapeutic targets against BBB and microenvironment are discussed.

2020 ◽  
pp. 209-220
Author(s):  
David K. C. Cooper ◽  
Abhijit Jagdale ◽  
Roslynn B. Mannon ◽  
Vineeta Kumar ◽  
Robert Gaston ◽  
...  

2020 ◽  
Vol 2 (3) ◽  
pp. 01-02
Author(s):  
Juana Pérez

Today, the success of conservative surgery in breast cancer depends not only on an appropriate selection of patients, but also on the combination of adequate surgical margins with an acceptable aesthetic result. Multiple causes, can influence the probability that these borders are affected by tumor, so in this work cytology of the section margins was performed at the time of the freeze biopsy, achieving as a fundamental purpose of the study, to guarantee the advantages of cytology Transoperative, as a safe tool in breast cancer conservative surgery, among other possibilities, which in the last decade have enabled, the decrease in reinterventions caused by this cause and improve the survival of patients.


Surgery ◽  
2021 ◽  
Author(s):  
Richard J. Straker ◽  
Danny H.J. Heo ◽  
Adrienne B. Shannon ◽  
Douglas L. Fraker ◽  
Skandan Shanmugan ◽  
...  

1990 ◽  
Vol 2 (6) ◽  
pp. 328-332 ◽  
Author(s):  
R.E. Coleman ◽  
I. Fogelman ◽  
F. Habibollahi ◽  
W.R.S. North ◽  
R.D. Rubens

1987 ◽  
Vol 6 (1-2) ◽  
pp. 34-39
Author(s):  
Alastair Compston

1978 ◽  
Vol 64 (5) ◽  
pp. 495-506 ◽  
Author(s):  
Zygmunt Paszko ◽  
Halina Padzik ◽  
Maria Dabska ◽  
Feliksa Pienkowska

The presence of estrogen receptors (ER) was determined in 111 human breast cancer specimens. In 61 % of the tumors, specific estrogen binding was found and in 39 % of the tumors ER was absent. In 69 tumors no correlation was found between the histological grading of the tumor and the level of ER. The values of ER in tumors from patients over 50 years of age were usually much higher than those for patients under 50 years of age. Different methods of endocrine therapy were applied in 20 patients. In 10 of 15 patients with ER positive tumors, endocrine therapy resulted in remission. Only 1 of 5 patients with ER negative tumors responded with remission. It is concluded that estimation of ER in tumor tissue is helpful in the selection of patients for endocrine therapy.


2007 ◽  
Vol 10 (1) ◽  
pp. 1-3 ◽  
Author(s):  
L. A. Schnaper ◽  
K. S. Hughes

Despite the fact that breast cancer is predominantly a disease of postmenopausal women, there have been no uniform recommendations for both locoregional and systemic therapy for women over 70. Until recently, older women have been excluded from clinical trials. This study is the first randomized trial that addresses the use of radiation therapy following lumpectomy in a favorable cohort of elderly women.


Sign in / Sign up

Export Citation Format

Share Document